Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SMMT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSummit Therapeutics establishes up to $380M at-the-market equity offering program
Filed July 23, 2026 · Period ending July 23, 2026 · ~1 min read
Key Changes
-
high
Summit entered into a distribution agreement with J.P. Morgan Securities to sell up to $380M of common stock over time through an at-the-market program, providing flexible capital access with no obligation to sell.
Item 1.01 verify on EDGAR → -
medium
The company will pay J.P. Morgan a commission of up to 3.0% of gross sales proceeds for shares sold under the program, with full discretion over timing, pricing, and volume of any sales.
Item 1.01 verify on EDGAR → -
low
The ATM program operates under Summit's shelf registration statement filed June 9, 2026, with a prospectus supplement filed July 23, 2026 to enable the offering.
Item 1.01 verify on EDGAR →
Summary
Summit Therapeutics established a $380 million at-the-market equity offering program with J.P. Morgan Securities as sales agent. The facility allows the company to sell common stock over time at prevailing market prices, providing flexible access to capital markets without the commitment or timing constraints of a traditional equity raise.
Summit retains full control over whether, when, and how much to sell, and may suspend the program at any time. For retail holders, the ATM represents potential dilution up to $380 million, though the actual impact depends entirely on how much Summit chooses to draw. The 3.0% commission is standard for ATM programs. The filing itself does not disclose Summit's intended use of proceeds or near-term capital needs, so investors should monitor subsequent disclosures about the company's cash position and funding requirements to gauge how aggressively the ATM might be utilized.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Summit Therapeutics established a $380M at-the-market equity offering program with J.P. Morgan Securities as sales agent.
Added in current filing · verify on EDGAR →
On July 23, 2026, Summit Therapeutics Inc. (the “Company”) entered into a distribution agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC (“Sales Agent”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of the Company’s common stock, par value $0.01 per share, having an aggregate offering price of up to $380,000,000 (the “Shares”).
Summit Therapeutics established an at-the-market equity offering facility allowing the company to sell up to $380 million of common stock over time through J.P. Morgan Securities as sales agent. The company has no obligation to sell any shares and may suspend the program at any time. This provides Summit with flexible access to capital markets to fund operations or strategic initiatives as needed.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 24, 2026 · How we verify